Surreal illustration of diabetes monitoring challenges in HIV patients.

A1c, Fructosamine, or Glucose? How to Monitor Diabetes in HIV Patients

Author's portrait.
Lena Kashyap in Health & Wellness July 2025 • 4 min read.

"Navigating the complexities of diabetes management in HIV-infected individuals: a practical guide to choosing the right monitoring method for accurate glycemic control."


Managing diabetes in HIV-infected patients presents unique challenges. The increased prevalence of abnormal glucose metabolism due to antiretroviral therapy (ART) and improved longevity necessitates careful monitoring. While general guidelines rely on hemoglobin A1c (HbA1c) for diabetes diagnosis and management, studies suggest that HbA1c values may be inappropriately low in HIV patients, leading to underestimated glycemia.

This article explores the complexities of monitoring glycemic control in HIV-infected individuals with diabetes. We'll delve into the accuracy of HbA1c, fructosamine, and glucose monitoring methods, providing insights to help healthcare providers and patients make informed decisions. The aim is to clarify which monitoring approach offers the most reliable assessment of blood sugar levels in this specific population.

Based on a comprehensive analysis, this guide aims to equip you with the knowledge to navigate these challenges effectively. By understanding the nuances of each monitoring method, we can strive for better diabetes management and improved health outcomes for HIV-infected patients.

HbA1c: Why It Might Not Tell the Whole Story in HIV Patients

Surreal illustration of diabetes monitoring challenges in HIV patients.

HbA1c, the standard marker for glycemic control, measures the percentage of glycated hemoglobin in the blood. However, several factors can affect its accuracy, including age, ethnicity, and conditions like cirrhosis and renal failure. In HIV-positive individuals, a chronic low-level hemolytic state (either from the viral infection itself or from ART) may lead to falsely low HbA1c values, resulting in an overestimation of glucose control.

A recent study investigated the correlation between HbA1c and actual glucose levels in HIV-positive patients with diabetes. The findings revealed:

  • HbA1c values underestimated actual average glucose (aAG) in 19% of patients and overestimated aAG in 27% of patients.
  • HbA1c estimated aAG within the established range in only 54% of patients.
  • The correlation between HbA1c and aAG was moderate (r=0.53, P<0.0001), indicating that HbA1c may not always accurately reflect average glucose levels in this population.
These findings emphasize the need for caution when relying solely on HbA1c to assess glycemic control in HIV-infected patients. Additional monitoring methods may be necessary to obtain a more accurate picture of blood sugar levels.

Making Informed Decisions for Better Diabetes Management

Monitoring diabetes in HIV-infected patients requires a nuanced approach. While HbA1c is a valuable tool, its limitations in this population necessitate the consideration of alternative methods like fructosamine and self-monitoring of blood glucose (SMBG).

By integrating multiple monitoring techniques and carefully considering individual patient factors, healthcare providers can develop personalized diabetes management plans that optimize glycemic control and improve overall health outcomes for HIV-infected individuals.

Further research is needed to fully elucidate the factors that affect HbA1c accuracy in HIV patients and to identify the most reliable strategies for diabetes monitoring. In the meantime, a comprehensive and individualized approach is essential to ensure optimal care.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.4137/cmed.s19202, Alternate LINK

Title: Monitoring Hiv-Infected Patients With Diabetes: Hemoglobin A1C, Fructosamine, Or Glucose?

Subject: Endocrinology, Diabetes and Metabolism

Journal: Clinical Medicine Insights: Endocrinology and Diabetes

Publisher: SAGE Publications

Authors: So-Young Kim, Patricia Friedmann, Amit Seth, Adrienne M. Fleckman

Published: 2014-01-01

Everything You Need To Know

1

Why might Hemoglobin A1c (HbA1c) alone not be sufficient for monitoring diabetes in HIV patients?

In HIV-positive individuals, relying solely on Hemoglobin A1c (HbA1c) to assess glycemic control can be problematic because certain factors, such as a chronic low-level hemolytic state (either from the viral infection itself or from antiretroviral therapy), may lead to falsely low HbA1c values, resulting in an overestimation of glucose control. This means HbA1c might suggest better glucose management than is actually the case.

2

Besides Hemoglobin A1c (HbA1c), what other methods can be used to monitor blood sugar in HIV patients with diabetes?

While Hemoglobin A1c (HbA1c) is a standard marker, its accuracy can be affected by factors like age, ethnicity, cirrhosis, and renal failure. In HIV patients, studies show HbA1c values may be inappropriately low, potentially underestimating glycemia. Therefore, additional monitoring methods such as fructosamine and self-monitoring of blood glucose (SMBG) are considered to get a more accurate assessment of blood sugar levels.

3

What did a recent study reveal about the accuracy of Hemoglobin A1c (HbA1c) in HIV-positive patients with diabetes?

The study revealed that Hemoglobin A1c (HbA1c) values underestimated actual average glucose (aAG) in 19% of patients and overestimated aAG in 27% of patients. Hemoglobin A1c (HbA1c) estimated aAG within the established range in only 54% of patients. The correlation between Hemoglobin A1c (HbA1c) and aAG was moderate (r=0.53, P<0.0001). Because of these results, healthcare providers need to be cautious when relying only on Hemoglobin A1c (HbA1c) and should consider other monitoring methods.

4

What makes managing diabetes in HIV-infected patients particularly challenging?

Managing diabetes in HIV-infected individuals presents unique challenges because antiretroviral therapy (ART) and improved longevity can lead to increased prevalence of abnormal glucose metabolism. This necessitates careful monitoring to ensure optimal glycemic control. Relying solely on Hemoglobin A1c (HbA1c) may not be sufficient, and alternative methods like fructosamine and self-monitoring of blood glucose (SMBG) should be considered for a more accurate assessment.

5

How does fructosamine compare to Hemoglobin A1c (HbA1c), and what role does self-monitoring of blood glucose (SMBG) play in managing diabetes?

Fructosamine offers an advantage over Hemoglobin A1c (HbA1c) by reflecting average blood glucose levels over a shorter period, typically 2-3 weeks, making it more responsive to recent changes in treatment or lifestyle. This is particularly useful when rapid adjustments to diabetes management are needed or when HbA1c results are unreliable. Self-monitoring of blood glucose (SMBG) allows for immediate insight into glucose levels at specific times, aiding in personalized management and informed decision-making regarding diet and medication. Although this article does not mention CGM (continuous glucose monitoring), it's also worth exploring to see glucose trends over time.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.